-DOCSTART- -X- O
Adjuvants -X- _ O
potentiate -X- _ O
antigen-specific -X- _ O
protective -X- _ O
immune -X- _ O
responses -X- _ O
and -X- _ O
can -X- _ O
be -X- _ O
key -X- _ O
elements -X- _ O
promoting -X- _ O
vaccine -X- _ O
effectiveness. -X- _ O
We -X- _ O
previously -X- _ O
reported -X- _ O
that -X- _ O
the -X- _ O
Onchocerca -X- _ B-Intervention
volvulus -X- _ I-Intervention
recombinant -X- _ I-Intervention
protein -X- _ I-Intervention
rOv-ASP-1 -X- _ I-Intervention
can -X- _ O
induce -X- _ O
activation -X- _ O
and -X- _ O
maturation -X- _ O
of -X- _ O
naïve -X- _ O
human -X- _ O
DCs -X- _ O
and -X- _ O
therefore -X- _ O
could -X- _ O
be -X- _ O
used -X- _ O
as -X- _ O
an -X- _ O
innate -X- _ O
adjuvant -X- _ O
to -X- _ O
promote -X- _ O
balanced -X- _ O
Th1 -X- _ O
and -X- _ O
Th2 -X- _ O
responses -X- _ O
to -X- _ O
bystander -X- _ O
vaccine -X- _ O
antigens -X- _ O
in -X- _ O
mice. -X- _ B-Patient
With -X- _ O
a -X- _ O
few -X- _ O
vaccine -X- _ O
antigens -X- _ O
, -X- _ O
it -X- _ O
also -X- _ O
promoted -X- _ O
a -X- _ O
Th1-biased -X- _ O
response -X- _ O
based -X- _ O
on -X- _ O
pronounced -X- _ O
induction -X- _ O
of -X- _ O
Th1-associated -X- _ O
IgG2a -X- _ O
and -X- _ O
IgG2b -X- _ O
antibody -X- _ O
responses -X- _ O
and -X- _ O
the -X- _ O
upregulated -X- _ O
production -X- _ O
of -X- _ O
Th1 -X- _ O
cytokines -X- _ O
, -X- _ O
including -X- _ O
IL-2 -X- _ O
, -X- _ O
IFN-γ -X- _ O
, -X- _ O
TNF-α -X- _ O
and -X- _ O
IL-6. -X- _ O
However -X- _ O
, -X- _ O
because -X- _ O
it -X- _ O
is -X- _ O
a -X- _ O
protein -X- _ O
, -X- _ O
the -X- _ O
rOv-ASP-1 -X- _ B-Intervention
adjuvant -X- _ I-Intervention
may -X- _ O
also -X- _ O
induce -X- _ O
anti-self- -X- _ O
antibodies. -X- _ O
Therefore -X- _ O
, -X- _ O
it -X- _ O
was -X- _ O
important -X- _ O
to -X- _ O
verify -X- _ O
that -X- _ O
the -X- _ O
host -X- _ O
responses -X- _ O
to -X- _ O
self -X- _ O
will -X- _ O
not -X- _ O
affect -X- _ O
the -X- _ O
adjuvanticity -X- _ B-Intervention
of -X- _ I-Intervention
rOv-ASP-1 -X- _ I-Intervention
when -X- _ O
it -X- _ O
is -X- _ O
used -X- _ O
in -X- _ O
subsequent -X- _ O
vaccinations -X- _ O
with -X- _ O
the -X- _ O
same -X- _ O
or -X- _ O
different -X- _ O
vaccine -X- _ O
antigens. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
established -X- _ O
rOv-ASP-1 -X- _ B-Intervention
's -X- _ I-Intervention
adjuvanticity -X- _ I-Intervention
in -X- _ O
mice -X- _ B-Patient
during -X- _ O
the -X- _ O
course -X- _ O
of -X- _ O
two -X- _ O
sequential -X- _ O
vaccinations -X- _ O
using -X- _ O
two -X- _ O
vaccine -X- _ O
model -X- _ O
systems -X- _ O
: -X- _ O
the -X- _ O
receptor-binding -X- _ O
domain -X- _ O
( -X- _ O
RBD -X- _ O
) -X- _ O
of -X- _ O
SARS-CoV -X- _ O
spike -X- _ O
protein -X- _ O
and -X- _ O
a -X- _ O
commercial -X- _ O
influenza -X- _ O
virus -X- _ O
hemagglutinin -X- _ O
( -X- _ O
HA -X- _ O
) -X- _ O
vaccine -X- _ O
comprised -X- _ O
of -X- _ O
three -X- _ O
virus -X- _ O
strains. -X- _ O
Moreover -X- _ O
, -X- _ O
the -X- _ O
adjuvanticity -X- _ B-Intervention
of -X- _ I-Intervention
rOv-ASP-1 -X- _ I-Intervention
was -X- _ O
retained -X- _ B-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
efficacy -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
that -X- _ I-Outcome
obtained -X- _ I-Outcome
when -X- _ I-Outcome
it -X- _ I-Outcome
was -X- _ I-Outcome
used -X- _ I-Outcome
for -X- _ I-Outcome
a -X- _ I-Outcome
first -X- _ I-Outcome
vaccination -X- _ I-Outcome
, -X- _ I-Outcome
even -X- _ I-Outcome
though -X- _ I-Outcome
a -X- _ I-Outcome
high -X- _ I-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
anti-rOv-ASP-1 -X- _ I-Outcome
antibodies -X- _ I-Outcome
was -X- _ I-Outcome
present -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
sera -X- _ I-Outcome
of -X- _ I-Outcome
mice -X- _ I-Outcome
before -X- _ I-Outcome
the -X- _ I-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
second -X- _ I-Outcome
vaccine. -X- _ I-Outcome
To -X- _ O
further -X- _ O
demonstrate -X- _ O
its -X- _ O
utility -X- _ O
as -X- _ O
an -X- _ O
adjuvant -X- _ O
for -X- _ O
human -X- _ O
use -X- _ O
, -X- _ O
we -X- _ O
also -X- _ O
immunized -X- _ O
non-human -X- _ B-Patient
primates -X- _ I-Patient
( -X- _ I-Patient
NHPs -X- _ I-Patient
) -X- _ I-Patient
with -X- _ O
RBD -X- _ B-Intervention
plus -X- _ I-Intervention
rOv-ASP-1 -X- _ I-Intervention
and -X- _ O
showed -X- _ O
that -X- _ O
rOv-ASP-1 -X- _ B-Outcome
could -X- _ I-Outcome
induce -X- _ I-Outcome
high -X- _ I-Outcome
titres -X- _ I-Outcome
of -X- _ I-Outcome
functional -X- _ I-Outcome
and -X- _ I-Outcome
protective -X- _ I-Outcome
anti-RBD -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ I-Outcome
NHPs. -X- _ I-Outcome
Notably -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
rOv-ASP-1 -X- _ I-Outcome
adjuvant -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
induce -X- _ I-Outcome
high -X- _ I-Outcome
titer -X- _ I-Outcome
antibodies -X- _ I-Outcome
against -X- _ I-Outcome
self -X- _ I-Outcome
in -X- _ I-Outcome
NHPs. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
provided -X- _ O
a -X- _ O
sound -X- _ O
scientific -X- _ O
foundation -X- _ O
for -X- _ O
future -X- _ O
strategies -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
this -X- _ O
novel -X- _ O
protein -X- _ O
adjuvant -X- _ O
. -X- _ O

